Published in J Immunol on February 15, 2004
The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity (2008) 10.55
NK cell development, homeostasis and function: parallels with CD8⁺ T cells. Nat Rev Immunol (2011) 3.38
The molecular basis of IL-21-mediated proliferation. Blood (2007) 2.90
A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A (2009) 2.46
NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol (2013) 2.39
Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors. J Exp Med (2005) 2.39
IL-21 mediates suppressive effects via its induction of IL-10. J Immunol (2009) 2.00
Activating receptors promote NK cell expansion for maintenance, IL-10 production, and CD8 T cell regulation during viral infection. J Exp Med (2009) 1.70
Posttranscriptional regulation of II10 gene expression allows natural killer cells to express immunoregulatory function. Immunity (2008) 1.65
Location and cellular stages of natural killer cell development. Trends Immunol (2013) 1.59
Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc Natl Acad Sci U S A (2010) 1.56
Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res (2011) 1.53
Interleukin 21: a cytokine/cytokine receptor system that has come of age. J Leukoc Biol (2008) 1.48
Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma. Blood (2015) 1.40
Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med (2005) 1.35
A requirement for CD45 distinguishes Ly49D-mediated cytokine and chemokine production from killing in primary natural killer cells. J Exp Med (2005) 1.35
Functions of γC cytokines in immune homeostasis: current and potential clinical applications. Clin Immunol (2009) 1.22
IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother (2008) 1.22
IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice. J Clin Invest (2008) 1.17
Interleukin-21: a multifunctional regulator of immunity to infections. Microbes Infect (2010) 1.17
The transcriptional control of the perforin locus. Immunol Rev (2010) 1.15
Regulation of mouse NK cell development and function by cytokines. Front Immunol (2013) 1.14
Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J Biomed Biotechnol (2011) 1.09
Early peritoneal immune response during Echinococcus granulosus establishment displays a biphasic behavior. PLoS Negl Trop Dis (2011) 1.08
Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood (2009) 1.07
The role of natural killer cells in tumor control--effectors and regulators of adaptive immunity. Springer Semin Immunopathol (2005) 1.04
Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology (2007) 1.03
Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med (2006) 1.02
Human natural killer cell development in secondary lymphoid tissues. Semin Immunol (2014) 1.01
Here today--not gone tomorrow: roles for activating receptors in sustaining NK cells during viral infections. Eur J Immunol (2010) 0.98
Association of NKG2A with treatment for chronic hepatitis C virus infection. Clin Exp Immunol (2010) 0.97
Ozone exposed epithelial cells modify cocultured natural killer cells. Am J Physiol Lung Cell Mol Physiol (2012) 0.96
TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS One (2011) 0.96
Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses. Cancer Res (2008) 0.94
Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo) (2014) 0.94
IL-21 augments natural killer effector functions in chronically HIV-infected individuals. AIDS (2008) 0.93
IL-21 is an antitolerogenic cytokine of the late-phase alloimmune response. Diabetes (2011) 0.92
Interleukin-15-deficient mice develop protective immunity to Toxoplasma gondii. Infect Immun (2004) 0.91
Interleukin (IL)-21-independent pathogen-specific CD8+ T-cell expansion, and IL-21-dependent suppression of CD4+ T-cell IL-17 production. Immunology (2010) 0.90
Expansion, maintenance, and memory in NK and T cells during viral infections: responding to pressures for defense and regulation. PLoS Pathog (2010) 0.90
Generation of a novel regulatory NK cell subset from peripheral blood CD34+ progenitors promoted by membrane-bound IL-15. PLoS One (2008) 0.90
Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation. J Immunother (2012) 0.90
Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumour responses. Immunology (2004) 0.88
Involvement of ERK-1/2 in IL-21-induced cytokine production in leukemia cells and human monocytes. Cytokine (2008) 0.86
Natural killer cells in patients with severe chronic fatigue syndrome. Auto Immun Highlights (2013) 0.86
Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer. Int J Biol Sci (2007) 0.85
Influence of in vitro IL-2 or IL-15 alone or in combination with Hsp-70-derived 14-mer peptide (TKD) on the expression of NK cell activatory and inhibitory receptors. Mediators Inflamm (2013) 0.85
Peripheral natural killer cell maturation depends on the transcription factor Aiolos. EMBO J (2014) 0.84
A high-efficiency system of natural killer cell cloning. J Immunol Methods (2005) 0.84
IL-21 Signaling in Immunity. F1000Res (2016) 0.84
IL-21: a pleiotropic cytokine with potential applications in oncology. J Immunol Res (2015) 0.83
Diversity, function, and transcriptional regulation of gut innate lymphocytes. Front Immunol (2013) 0.83
Proliferation conditions promote intrinsic changes in NK cells for an IL-10 response. J Immunol (2014) 0.81
Interleukin 21 up-regulates perforin-mediated cytotoxic activity of human intra-epithelial lymphocytes. Immunology (2009) 0.81
Diesel exhaust particles modify natural killer cell function and cytokine release. Part Fibre Toxicol (2013) 0.81
Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models. PLoS One (2013) 0.81
Interleukin-21 receptor signalling is important for innate immune protection against HSV-2 infections. PLoS One (2013) 0.81
Comparison of vascular leak syndrome in mice treated with IL21 or IL2. Comp Med (2013) 0.80
Stage-Specific Role of Interferon-Gamma in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. Front Immunol (2015) 0.80
Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma. Oncoimmunology (2016) 0.78
Antigen-specific human NKT cells from tuberculosis patients produce IL-21 to help B cells for the production of immunoglobulins. Oncotarget (2015) 0.78
Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies-A review. Oncoimmunology (2015) 0.78
IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. Clin Cancer Res (2016) 0.77
IL-21 Modulates Activation of NKT Cells in Patients with Stage IV Malignant Melanoma. Clin Transl Immunology (2013) 0.76
Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation. Front Immunol (2017) 0.76
Intratumoral natural killer cells show reduced effector and cytolytic properties and control the differentiation of effector Th1 cells. Oncoimmunology (2016) 0.75
Type I Interferons and Natural Killer Cell Regulation in Cancer. Front Immunol (2017) 0.75
STATs in NK-Cells: The Good, the Bad, and the Ugly. Front Immunol (2017) 0.75
Chitosan nanoparticle-based delivery of fused NKG2D-IL-21 gene suppresses colon cancer growth in mice. Int J Nanomedicine (2017) 0.75
Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor. Oncoimmunology (2017) 0.75
GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity. Blood (2016) 0.75
Mechanism involved in interleukin-21-induced phagocytosis in human monocytes and macrophages. Clin Exp Immunol (2016) 0.75
A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma. Front Immunol (2017) 0.75
Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers. Front Immunol (2017) 0.75
GSK 3 inhibition drives maturation of NK cells and enhances their antitumor activity. Cancer Res (2017) 0.75
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Tumor growth need not be driven by rare cancer stem cells. Science (2007) 10.34
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
NKT cells: what's in a name? Nat Rev Immunol (2004) 7.84
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
STING is a direct innate immune sensor of cyclic di-GMP. Nature (2011) 6.44
Immune surveillance of tumors. J Clin Invest (2007) 5.04
IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med (2010) 4.65
CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol (2006) 4.48
The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 4.42
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Analysis of Pseudomonas aeruginosa diguanylate cyclases and phosphodiesterases reveals a role for bis-(3'-5')-cyclic-GMP in virulence. Proc Natl Acad Sci U S A (2006) 4.33
IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med (2010) 4.04
The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat Immunol (2010) 3.97
Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol (2002) 3.96
The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect Immun (2010) 3.89
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73
Blimp-1 transcription factor is required for the differentiation of effector CD8(+) T cells and memory responses. Immunity (2009) 3.66
A cyclic-di-GMP receptor required for bacterial exopolysaccharide production. Mol Microbiol (2007) 3.54
The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells. Nat Immunol (2011) 3.44
New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer (2002) 3.38
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood (2010) 3.23
Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol (2002) 3.20
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A (2008) 3.19
A natural killer T (NKT) cell developmental pathway iInvolving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage. J Exp Med (2002) 3.13
The second messenger bis-(3'-5')-cyclic-GMP and its PilZ domain-containing receptor Alg44 are required for alginate biosynthesis in Pseudomonas aeruginosa. Mol Microbiol (2007) 3.11
Transcriptional repressor Blimp-1 is essential for T cell homeostasis and self-tolerance. Nat Immunol (2006) 3.09
The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep (2013) 3.08
Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol (2006) 3.04
IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol (2007) 2.99
A network of PDZ-containing proteins regulates T cell polarity and morphology during migration and immunological synapse formation. Immunity (2005) 2.97
A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J Exp Med (2009) 2.92
Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity (2009) 2.89
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 2.88
Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med (2005) 2.83
Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol (2005) 2.77
Plasma cell ontogeny defined by quantitative changes in blimp-1 expression. J Exp Med (2004) 2.76
M-CSF instructs myeloid lineage fate in single haematopoietic stem cells. Nature (2013) 2.74
A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med (2002) 2.73
BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med (2007) 2.70
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A (2010) 2.67
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med (2012) 2.66
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res (2013) 2.62
Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity (2009) 2.61
Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1. Immunity (2007) 2.61
Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res (2011) 2.59
Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci U S A (2008) 2.57
Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature (2009) 2.54
The transcription factor PU.1 controls dendritic cell development and Flt3 cytokine receptor expression in a dose-dependent manner. Immunity (2010) 2.53
Early appearance of germinal center-derived memory B cells and plasma cells in blood after primary immunization. J Exp Med (2005) 2.51
Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol (2003) 2.48
The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T cells. Nat Immunol (2013) 2.48
Mcl-1 is essential for germinal center formation and B cell memory. Science (2010) 2.42
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35
PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis. J Exp Med (2005) 2.34
A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med (2005) 2.32
Positive feedback between PU.1 and the cell cycle controls myeloid differentiation. Science (2013) 2.31
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30
NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J Immunol (2007) 2.26
Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol (2011) 2.21
NKG2D function protects the host from tumor initiation. J Exp Med (2005) 2.19
Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis. J Immunol (2008) 2.19
High affinity germinal center B cells are actively selected into the plasma cell compartment. J Exp Med (2006) 2.19
Control of formation and cellular detachment from Shewanella oneidensis MR-1 biofilms by cyclic di-GMP. J Bacteriol (2006) 2.15
The development and fate of follicular helper T cells defined by an IL-21 reporter mouse. Nat Immunol (2012) 2.14
Bacterial c-di-GMP is an immunostimulatory molecule. J Immunol (2007) 2.13
Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med (2006) 2.10
CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol (2006) 2.10
Cytokines in cancer immunity and immunotherapy. Immunol Rev (2004) 2.09
Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol (2005) 2.08
Innate immunity defines the capacity of antiviral T cells to limit persistent infection. J Exp Med (2010) 2.06
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res (2011) 2.03
Activation of NK cell cytotoxicity. Mol Immunol (2005) 2.03
DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med (2008) 2.00
Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat Immunol (2007) 1.97
Functional subsets of mouse natural killer cells. Immunol Rev (2006) 1.95
Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol (2010) 1.94
NKT cells - conductors of tumor immunity? Curr Opin Immunol (2002) 1.94
Identification of Bcl-6-dependent follicular helper NKT cells that provide cognate help for B cell responses. Nat Immunol (2011) 1.94
Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med (2012) 1.93
Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood (2009) 1.91
FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity (2007) 1.90
Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med (2002) 1.88
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res (2011) 1.88
Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med (2002) 1.85
Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol (2007) 1.84